Santarus, Inc. and Pharming Group NV Company Profile

News Articles [ 189 Associated News Articles listed on BioPortfolio]

Pharming Group N.V.: Pharming and Santarus announce submission of RUCONEST Biologics License Application to FDA

LEIDEN, The Netherlands and SAN DIEGO, Calif. (April 17, 2013) -Pharming Group NV (NYSE Euronext: PHARM) and Santarus, Inc. (NASDAQ: SNTS) today announced the submission of a Biologics License App...

Pharming gets $10 million milestone from Santarus on Ruconest progress

Loss-making Dutch biotech company Pharming Group NV (NYSE Euronext: PHARM) said yesterday that, following the release by Pharming and Santarus (Nasdaq: SNTS) on November 7 of the pivotal Phase III cli...

Pharming tries again with Ruconest BLA

Pharming Group N.V. (Euronext:PHARM) and partner Santarus Inc. (NASDAQ:SNTS) said Pharming submitted a BLA to FDA for Ruconest conestat alfa to treat acute attacks of hereditary angioedema (HAE). FDA...

BRIEF-Pharming gets good phase III results for Ruconest

BRUSSELS, Nov 7 (Reuters) - Pharming Group NV : * Santarus and Pharming announce positive top-line phase III results for

Pharming/Santarus make second US attempt with Ruconest

Pharming and Santarus have submitted a second biologics license application (BLA) to the US FDA to obtain marketing approval for Ruconest (recombinant human C1 esterase inhibitor) 50U/kg for the treat...

Pharming and Santarus file BLA for Ruconest with US FDA

Netherlands-based Pharming Group (NYSE Euronext: PHARM) and US licensee Santarus (Nasdaq: SNTS) have submitted a Biologics License Application (BLA) to the US Food and Drug Administration to obtain ma...

Pharming Group N.V.: Pharming announces receipt of US$10 million milestone payment

Leiden, The Netherlands, November, 26, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that following the announcement by Pharming and ...

Rhucin meets Phase III HAE endpoint

Pharming Group N.V. (Euronext:PHARM) and partner Santarus Inc. (NASDAQ:SNTS) reported top-line data showing that a single IV infusion of 50 units/kg Rhucin conestat alfa met the primary endpoint of re...

Drugs and Medications [ 46 Associated Drugs and Medications listed on BioPortfolio]

Cycloset [Santarus, Inc.]

These highlights do not include all the information needed to use CYCLOSET safely and effectively. See full prescribing information for CYCLOSET. CYCLOSET (bromocriptine mesylate) Tablets, oralInitial...

Ethyl alcohol [H and P Industries, Inc. dba Triad Group]

DRUG FACTS

Triadine prep [Triad Group]

DRUG FACTS

Glycerin [H and P Industries, Inc. dba Triad Group]

DRUG FACTS

Alba hawaiian coconut siscreen spf 15 [The Hain Celestial Group, Inc.]

Drug Facts

PubMed Articles [ 2 Associated PubMed Articles listed on BioPortfolio]

Expression of the major mugwort pollen allergen Art v 1 in tobacco plants and cell cultures: problems and perspectives for allergen production in plants.

An economic and cheap production of large amounts of recombinant allergenic proteins might become a prerequisite for the common use of microarray-based diagnostic allergy assays which allow a componen...

Proteomics-based, multivariate random forest method for prediction of protein separation behavior during cation-exchange chromatography.

The most significant cost of recombinant protein production lies in the optimization of the downstream purification methods, mainly due to a lack of knowledge of the separation behavior of the host ce...

Clinical Trials [ 1327 Associated Clinical Trials listed on BioPortfolio]

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Short Term Group Therapy for OCD

Assessing OCD before and after group therapy

Psychological Prevention of Internalizing Disorders

The purpose of this study is to determine whether cognitive-behavioral group prevention (CBT-G) for german children is effective and to what extent parental group training moderates outcom...

Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the pati...

Clinical Trial of Donepezil Between the Naive Group and the Switching Group

To compare the clinical efficacy of donepezil between the naive group and the switching group.

Companies [ 1318 Associated Companies listed on BioPortfolio]

Santarus, Inc. and Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST™ (RHUCIN® in non-European territories) is a recombinant human C1 inh...

Santarus, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gas...

Santarus, Inc. & Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by phy...

Santarus, Inc. and Depomed, Inc.

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by phy...

PHARMING

At Pharming we strive to develop outstanding therapies for a range of medical needs based on our unique science and technology. We specialize in the production of human proteins with healthcare potent...